Bayesian Health's AI sepsis monitor receives FDA clearance
Bayesian Health's AI-driven sepsis monitor has received FDA clearance, marking a milestone as the first product of its kind to do so. The device continuously analyzes patient data to detect sepsis early, enhancing clinical decision-making.
The U.S. Food and Drug Administration (FDA) has awarded Bayesian Health clearance for their artificial intelligence (AI)-powered continuous sepsis monitor, according to an announcement. The company reported that this is the first product of its kind to achieve FDA clearance.
Bayesian Health emphasized that their device is reliable. It “continuously reasons over evolving patient state across all data types, rather than triggering on episodic rules.” It identifies sepsis and sepsis-related complications early and flags healthcare providers.
The device is also expected to receive approval from the Centers for Medicare and Medicaid Services' New Technology Add-on Payment (NTAP) in August.
